Requests that the FDA immediately require the addition of boxed warnings, warning, preacautions, and highlights of prescribing information to the product label for all selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor products, including branded and generic formulations to warn of serious and severe risks.